Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-002834-20-AT
EUCTR2004-002834-20-AT
Active, not recruiting
Not Applicable

Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001)Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-001) - treatment of HCC with rapamycin

niversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie0 sites30 target enrollmentJanuary 23, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAdvanced hepatocellular carcinoma (HCC)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Advanced hepatocellular carcinoma (HCC)
Sponsor
niversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie
Enrollment
30
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 23, 2008
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie

Eligibility Criteria

Inclusion Criteria

  • •histologically verified hepatocellular carcinoma, not suitable for surgery, liver transplantation, embolization, kryotherpay, ethanol instillation, radio frequency ablation.
  • •No previous therapy
  • •liver cirrhosis Child A or B
  • •Thrombocytes \> 30\.0 x 10E9 / L
  • •Leukozyten \> 1\.0 x 10E9 / L
  • •Age 19 \- 85
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •WHO performance status \> 2
  • •estimated life expectancy \< 3 months
  • •acute infection
  • •HIV positivity
  • •pregnancy, breast feeding, lack of contraception
  • •other malignant disease within past 5 years

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinoma
DRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200
Not yet recruiting
Not Applicable
Systemic therapy for Unresectable Hepatocellular Carcinoma: Therapeutic Effectiveness by Treatment Modality and Optimal Drug Use Ordernresectable hepatocellular carcinoma
JPRN-UMIN000051797Japanese Red Cross Society Himeji Hospital5,000
Active, not recruiting
Not Applicable
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713
EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Not yet recruiting
Not Applicable
Resection of initially unresectable hepatocellular carcinoma with atezolizumab plus bevacizumab Additional study: Identification of biomarkers for predicting therapeutic effects and adverse events
JPRN-UMIN000046634ational Center for Global Health and Medicine50
Recruiting
Not Applicable
RACB StudyHepatocellular Carcinoma
JPRN-jRCTs051210148Hatano Etsuro50